Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)

NCT: NCT06417853 · COMPLETED

NCT IDNCT06417853
StatusCOMPLETED
Start Date2024-07-31
Completion2026-01-30

Brief Summary

Study SP-1219-007 is a multi-centre, randomised, study designed to access the safety and tolerability of two doses of monovalent Influenza A (H7N9) vaccine delivered intradermally by a microarray patch delivery system in healthy adults aged 18 to 50 years.

Frequently Asked Questions

What is Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)?

Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) is a clinical trial registered under NCT06417853. Current status: COMPLETED.

What is the status of NCT06417853?

The current status of NCT06417853 (Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)) is: COMPLETED.

When did Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) start?

Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) started on 2024-07-31.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑